ESCRS - PO0832 - The Application Of The Modern Formula Eye Drops In Lipid Deficiency Dry Eye Disease – One Site Observations

The Application Of The Modern Formula Eye Drops In Lipid Deficiency Dry Eye Disease – One Site Observations

Published 2023 - 41st Congress of the ESCRS

Reference: PO0832 | DOI: 10.82333/heef-a709

Authors: Ewa Mrukwa-Kominek* 1 , Michał Bogocz 1 , Sylwia Wagner 2

1Department of Ophthalmology, Faculty of Medical Sciences in Katowice,Medical University of Silesia ,Katowice,Poland;Department of Ophthalmology,Prof Gibinski's Univesity Clinical Center, Medical University of Silesia,Katowice,Poland, 2Department of Ophthalmology,Prof Gibinski's Univesity Clinical Center, Medical University of Silesia,Katowice,Poland

Assessment of the effectiveness of the lipid eye drops in patients with the dry eye disease and deficiency of the lipid phase. Indication of the benefits resulting from using these eye drops to protect the ocular surface, control tears evaporation and provide long lasting relief of dry eye symptoms.

  1. Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland
  2. Department of Ophthalmology, Prof Gibinski's Univesity Clinical Center, Medical University of Silesia

Thirty patients (60 eyes) aged 38 to 72 (mean age 53.23 ) with the dry eye syndrome and deficiency of the lipid phase were enrolled into the study. The eye drops Thealipid (Thea, France) were administered 3 times per day for 30 days. The assessment of the eye drops effectiveness was based on: (1) alterations of the tear film stability (Schirmer test, break-up-time BUT, corneal staining, changes in anterior surface of the cornea), (2) subjective symptoms, (3)  intensity of discomfort, (4) quality of life, and (5) changes in the structure of the cornea verified in a confocal microscope.

There was no statistically significant changes in visual acuity and intraocular pressure. Mean OSDI was 52 and 26.07 before and after therapy, respectively, showing statistically significant reduction. Corneal topography changes in K1 and K2 was significant (p<0.05). Mean Schirmer test result was 15.86 before and increased up to 18.17 after treatment. First BUT interruption was 11.8, next 12.54 sec. BUT increased to 16.45 and 17.80, respectively. After 30 days of treatment the changes in the anterior part of the cornea, especially in the corneal epithelium, were less severe

Application of the eye drops resulted in: (1) increase of the stability of the tear film (verified with BUT, corneal staining), (2) reduction of subjective symptoms, (3) improvement of comfort and quality of life, and (4) beneficial changes in the structure of the cornea.